For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Mesalazine - Inflammatory bowel disease
PAD Profile : Mesalazine - Inflammatory bowel disease Important
Traffic Light Status
Status 1 of 5.
- Gastro-resistant tablets
Status 2 of 5.
- Suppositories
Status 3 of 5.
- Modified release tablets
Status 4 of 5.
- Granules (slow release)
- Modified release tablets
Status 5 of 5.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Mesalazine therapy is included within the locally agreed pathway for Ulcerative Colitis (see pathway document below).
Mesalazine therapy should be prescribed by BRAND. The following brands have been considered by the APC:
- Salofalk® gastro-resistant tablets and granules - 1st line for new patients
- Octasa® MR gastro-resistant tablets - 1st line for new patients
- Pentasa® modified-release tablets and granules - 1st line for patients who require upper GI release
- Mezavant® XL tablets - Alternative choice for patients with high pill burden
Choice is dependent on required site of release and factors that may aid adherence to therapy. Prescribe by brand to ensure continuation of those chosen properties
Asacol® MR gastro-resistant tablets are non-formulary and least cost-effective option - can continue in existing patients with good disease control (see separate page https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6208). Octasa® MR has the same release properties as Asacol® MR